Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +0.79% | -6.27% | -13.90% |
Sales 2024 * | 3.45M 275M | Sales 2025 * | 9.13M 730M | Capitalization | 94.07M 7.51B |
---|---|---|---|---|---|
Net income 2024 * | -97M -7.75B | Net income 2025 * | -83M -6.63B | EV / Sales 2024 * | 63.5 x |
Net Debt 2024 * | 125M 9.99B | Net Debt 2025 * | 115M 9.16B | EV / Sales 2025 * | 22.8 x |
P/E ratio 2024 * |
-0.91
x | P/E ratio 2025 * |
-1.44
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.61% |
Latest transcript on BioXcel Therapeutics, Inc.
1 day | +0.79% | ||
1 week | -6.27% | ||
Current month | +0.79% | ||
1 month | -9.93% | ||
3 months | -20.13% | ||
6 months | -42.14% | ||
Current year | -13.90% |
Managers | Title | Age | Since |
---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 28/03/17 |
Director of Finance/CFO | 66 | 30/09/17 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/05/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 30/06/22 |
Peter Mueller
CHM | Chairman | 68 | 31/03/17 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 31/08/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 9 M€ | +5.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 2.54 | +0.79% | 210,560 |
30/04/24 | 2.52 | -2.33% | 164,938 |
29/04/24 | 2.58 | -1.90% | 339,321 |
26/04/24 | 2.63 | +0.77% | 260,297 |
25/04/24 | 2.61 | -3.69% | 665,832 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.90% | 94.07M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.19% | 22.25B | |
-14.77% | 21.68B | |
-8.82% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- BTAI Stock